NetworkNewsBreaks – Albireo Pharma, Inc. (NASDAQ: ALBO) Closes $74.8M Public Offering
Albireo Pharma (NASDAQ: ALBO), a biopharmaceutical company focused on development of treatments for orphan pediatric liver diseases and other diseases and disorders, completed its underwritten public offering of 1,970,000 common stock shares at a public price of $33.00 per share. The underwriters have also exercised an option for the purchase of an additional 295,500 common stock shares at the public offering price, less the underwriting discounts and commissions. Albireo sold all of the offering shares and grossed proceeds of approximately $74.8 million while netting proceeds of approximately $69.9 million. To view the full press release, visit http://nnw.fm/WPZ7t About Albireo Albireo…







